^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Prostatic acid phosphatase inhibitor

    Related drugs:
    1m
    177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    PSAP (Prostatic Acid Phosphatase)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Provenge (sipuleucel-T)
    3ms
    Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors. (PubMed, Immunotargets Ther)
    Prior to the advent of ICIs, prostate cancer had one of the first approvals for cancer immunotherapy with sipleucel-T, an anti-cancer vaccine...Most notably, clinical trials with bispecific T-cell engagers (BiTEs) targeting tumor antigens like STEAP-1 and KLK2 have shown clinical promise. Moving beyond ICIs may lead to new approaches to alter the prostate cancer tumor immune microenvironment and improve clinical outcomes.
    Review • Journal • Checkpoint inhibition
    |
    STEAP1 (STEAP Family Member 1) • KLK2 (Kallikrein-related peptidase 2)
    |
    Provenge (sipuleucel-T)
    3ms
    Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=26, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • apalutamide • Provenge (sipuleucel-T)
    3ms
    ProvONE: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T (clinicaltrials.gov)
    P2, N=400, Recruiting, Dendreon | Not yet recruiting --> Recruiting | Phase classification: P3 --> P2
    Enrollment open • Phase classification
    |
    Provenge (sipuleucel-T)
    4ms
    Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, University of Wisconsin, Madison
    New P1 trial
    |
    Opdivo (nivolumab) • MVI-816
    7ms
    Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=26, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Mar 2025 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • apalutamide • Provenge (sipuleucel-T)
    9ms
    OU-SCC-EXCITE: Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=13, Recruiting, University of Oklahoma | Trial completion date: Nov 2024 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Provenge (sipuleucel-T)
    11ms
    The safety and efficacy study of Sipuleucel-T combined with platinum-based chemotherapy for neoadjuvant treatment in patients with locally advanced cervical cancer (multicenter). (ChiCTR2400094708)
    P1, N=33, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New P1 trial
    |
    Provenge (sipuleucel-T)
    1year
    ProVent: Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (clinicaltrials.gov)
    P3, N=532, Completed, Dendreon | Active, not recruiting --> Completed
    Trial completion
    |
    Provenge (sipuleucel-T)
    1year
    Peripheral blood interferon responses to toll-like receptor 1/2 signaling associate with longer survival in men with metastatic prostate cancer treated with Sipleucel-T. (PubMed, Cancer Res Commun)
    IFN-β responses to TLR1/2 signaling correlated with increased numbers of IFN-β producing T cells after broad, tumor antigen independent stimulation. Thus, peripheral innate immunity differs by race, may predict survival after sip-T, and associates with peripheral T cell functionality in men with mCRPC.
    Journal • IO biomarker • Metastases
    |
    IFNB1 (Interferon Beta 1)
    |
    Provenge (sipuleucel-T)
    over1year
    Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer. (PubMed, Hum Vaccin Immunother)
    The presence of T-cells specific for the PAP target antigen was detectable in 6/10 (60%) individuals with nmCSPC, and 3/5 (60%) individuals with nmCRPC, many years after immunization. The detection of immune responses to the vaccine target years after immunization suggests durable immunity can be elicited in patients using a DNA vaccine encoding a tumor-associated antigen.Trial Registration: NCT00582140 and NCT00849121.
    Journal
    |
    CSF2 (Colony stimulating factor 2) • PSAP (Prostatic Acid Phosphatase)
    |
    MVI-816
    over1year
    Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=26, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Oct 2025 --> Oct 2024
    Trial primary completion date • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • apalutamide • Provenge (sipuleucel-T)